Reference

CEM_CMO(2022)002

Name

COVID-19 Therapeutic Alert: Antivirals and neutralising monoclonal antibodies in the treatment of COVID-19 in hospitalised patients

Categories

Scottish Government CMO Letters

Organization

Scottish Government Health and Social Care Directorates

Keywords

NHS SCOTLAND COVID-19 CORONAVIRUS TREATMENTS DRUGS ANTIBODIES PATIENTS HOSPITALS

Description

This CMO letter further updates to the UK-wide clinical commissioning policy (for implementation from 10 February 2022) to add an additional antiviral treatment option PF-07321332 (may also be known as nirmatrelvir) plus ritonavir (Paxlovid) as a first-line treatment option for patients with hospital onset COVID infection. The intravenous antiviral remdesivir (Veklury) and the monoclonal antibody sotrovimab (Xevudy) remaining available as alternative treatment options for dissemination to relevant healthcare professionals for onward transmission as detailed in the letter.

Contact Name

Irene Fazakerley

Contact Email

Contact Address

St Andrew’s House Regent Road Edinburgh EH1 3DG

Contact Phone

Created

2022-01-27 00:00:00

Download URL